5′ unlocked nucleic acid modification improves siRNA targeting

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages

  Snead, Nicholas M ^a   Escamilla Powers, Julie R ^b   Rossi, John J ^a   McCaffrey, Anton P ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b TriLink BioTechnologies   (United States)

Author keywords

Nucleic acid chemistries; siRNAs, shRNAs, and miRNAs

Indexed keywords

NUCLEIC ACID; SMALL INTERFERING RNA;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; GENE SILENCING; GENE TARGETING; HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL;

EID: 84880110211     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.36     Document Type: Article

References (24)

1. Takahashi, M, Watanabe, S, Murata, M, Furuya, H, Kanazawa, I, Wada, K et al. (2010). Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc Natl Acad Sci USA 107: 21731-21736.
2. de Yñigo-Mojado, L, Martín-Ruíz, I and Sutherland, JD (2011). Effcient allele-specifc targeting of LRRK2 R1441 mutations mediated by RNAi. PLoS ONE 6: e21352.
3. Goldberg, MS and Sharp, PA (2012). Pyruvate kinase M2-specifc siRNA induces apoptosis and tumor regression. J Exp Med 209: 217-224.
4. Khvorova, A, Reynolds, A and Jayasena, SD (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216. (Pubitemid 37329584)
5. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208. (Pubitemid 37329583)
6. Sun, X, Rogoff, HA and Li, CJ (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol 26: 1379-1382.
7. Chang, CI, Yoo, JW, Hong, SW, Lee, SE, Kang, HS, Sun, X et al. (2009). Asymmetric shorter-duplex siRNA structures trigger effcient gene silencing with reduced nonspecifc effects. Mol Ther 17: 725-732.
8. Wu, H, Ma, H, Ye, C, Ramirez, D, Chen, S, Montoya, J et al. (2011). Improved siRNA/shRNA functionality by mismatched duplex. PLoS ONE 6: e28580.
9. Chen, PY, Weinmann, L, Gaidatzis, D, Pei, Y, Zavolan, M, Tuschl, T et al. (2008). Strand-specifc 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specifcity. RNA 14: 263-274. (Pubitemid 351171587)
10. Langkjaer, N, Pasternak, A and Wengel, J (2009). UNA (unlocked nucleic acid): a fexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem 17: 5420-5425.
11. Pasternak, A and Wengel, J (2010). Thermodynamics of RNA duplexes modifed with unlocked nucleic acid nucleotides. Nucleic Acids Res 38: 6697-6706.
12. Kenski, DM, Cooper, AJ, Li, JJ, Willingham, AT, Haringsma, HJ, Young, TA et al. (2010). Analysis of acyclic nucleoside modifcations in siRNAs fnds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res 38: 660-671.
13. Bramsen, JB, Pakula, MM, Hansen, TB, Bus, C, Langkjær, N, Odadzic, D et al. (2010). A screen of chemical modifcations identifes position-specifc modifcation by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 38: 5761-5773.
14. Vaish, N, Chen, F, Seth, S, Fosnaugh, K, Liu, Y, Adami, R et al. (2011). Improved specifcity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res 39: 1823-1832.
15. Laursen, MB, Pakula, MM, Gao, S, Fluiter, K, Mook, OR, Baas, F et al. (2010). Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst 6: 862-870.
16. Kim, DH, Behlke, MA, Rose, SD, Chang, MS, Choi, S and Rossi, JJ (2005). Synthetic dsRNA Dicer substrates enhance RNAi potency and effcacy. Nat Biotechnol 23: 222-226. (Pubitemid 40255333)
17. Rose, SD, Kim, DH, Amarzguioui, M, Heidel, JD, Collingwood, MA, Davis, ME et al. (2005). Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res 33: 4140-4156. (Pubitemid 41487274)
18. Beerens, N, Groot, F and Berkhout, B (2000). Stabilization of the U5-leader stem in the HIV-1 RNA genome affects initiation and elongation of reverse transcription. Nucleic Acids Res 28: 4130-4137.
19. Sakurai, K, Amarzguioui, M, Kim, DH, Alluin, J, Heale, B, Song, MS et al. (2011). A role for human Dicer in pre-RISC loading of siRNAs. Nucleic Acids Res 39: 1510-1525.
20. Heale, BS, Soifer, HS, Bowers, C and Rossi, JJ (2005). siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res 33: e30.
21. Seth, S, Matsui, Y, Fosnaugh, K, Liu, Y, Vaish, N, Adami, R et al. (2011). RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 19: 928-935.
22. Chen, BK, Saksela, K, Andino, R and Baltimore, D (1994). Distinct modes of human immunodefciency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol 68: 654-660. (Pubitemid 24022165)
23. Meister, G, Landthaler, M, Patkaniowska, A, Dorsett, Y, Teng, G and Tuschl, T (2004). Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 15: 185-197. (Pubitemid 38950966)
24. Zhou, J, Li, H, Li, S, Zaia, J and Rossi, JJ (2008). Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 16: 1481-1489.